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ABSTRAK 
 
Kanser payudara adalah salah satu kanser malignan yang biasa berlaku dalam kalangan 
wanita di seluruh dunia. Terdapat permintaan yang berterusan untuk terapi baru bagi 
merawat penyakit yang kompleks ini. Dapat diperhatikan, penyelidikan saintifik 
sedang menumpukan perhatian ke arah tumbuhan berubat yang berpotensi menjadi 
sumber kepada agen antikanser. Christia vespertilionis adalah tumbuhan tempatan 
yang dikatakan mempunyai sifat antikanser. Ia banyak dipasarkan sebagai makanan 
tambahan di Malaysia sekali gus membangkitkan persoalaan mengenai keselamatan 
dan keberkesanan tumbuhan ini. Tambahan lagi, penyelidikan semasa mengenai 
potensi mekanisma antikanser tumbuhan ini juga adalah terhad. Oleh itu, kajian ini 
bertujuan untuk menilai keberkesanan ekstrak-ekstrak C. vespertilionis terhadap sel-
sel kanser payudara (MDA-MB-231 dan MCF-7) dan untuk menyiasat cara kematian 
sel yang diakibatkan oleh ekstrak tersebut. Di samping itu, sebatian kimia dalam 
CVME dan unsur-unsur logam tumbuhan ini juga dikaji. Aktiviti ketoksikan terhadap 
sel oleh CVME, CVAE dan tamoxifen dinilai oleh eksperimen MTT manakala cara 
kematian sel adalah dinilai oleh penggunaan pewarna Annexin V-FITC dan PI. 
Analisis sebatian kimia dan unsur-unsur logan disiasat menggunakan GC-MS dan 
ICP-MS. Hasil eksperimen MTT menunjukkan bahawa CVME mempunyai kesan 
ketara dalam menghalang pertumbuhan sel-sel MDA-MB-231 (p<0.05) dan kesannya 
adalah melalui ketoksikan sel terpilih iaitu terhadap sel-sel kanser sahaja. Selain itu, 
kajian ini mendedahkan bahawa CVME menyebabkan sel-sel mati melalui cara 
apoptosis yang ditunjukkan melalui peningkatan peratusan sel-sel apoptosis (p<0.05) 
jika dibandingkan dengan sel-sel kanser yang tidak dirawat. CVME juga didapati 
mengandungi beberapa sebatian kimia yang aktif dan memiliki aktviti antikanser 
 x 
 
seperti phytol dan asid 10-undecenoic. Analisis unsur logam merbahaya juga 
mendedahkan bahawa tumbuhan ini mengandungi kandungan kromium yang tinggi 
yang boleh menyebabkan kesan-kesan sampingan yang berbahaya. Sebagai 
kesimpulan, kajian ini menunjukkan C. vespertilionis mempunyai potensi untuk 
dijadikan sumber rawatan bagi kanser payudara. 
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ABSTRACT 
 
Breast cancer is one of the common malignancies among women worldwide. There is 
a constant demand for new therapies to treat this complex disease. Notably, scientific 
research is drawing its attention towards medicinal plants as a potential source for 
anticancer agents. Christia vespertilionis is a local herb claimed to have anticancer 
properties. It is widely marketed as a food supplement in Malaysia thus raise an 
awareness regarding their efficacy and safety. Moreover, current research about the 
mechanisms of its anticancer potential is also limited. Herein, this study aimed to 
evaluate the efficacy of C. vespertilionis extracts on breast cancer cell lines (MDA-
MB-231 and MCF-7) and to investigate the mode of cell death that underlies its 
anticancer effects. Besides, the phytochemical in CVME and heavy metals of the plant 
were also investigated. The cytotoxic activities of CVME, CVAE and tamoxifen was 
evaluated by MTT assay while the mode of cell death was evaluated by Annexin V-
FITC and PI staining. The phytochemical and heavy metal analysis were investigated 
by GC-MS and ICP-MS, respectively. Results from MTT assay showed that CVME 
significantly inhibits proliferation of MDA-MB-231 cells line (p<0.05) and the effect 
was selectively cytotoxic towards cancerous cells only.  Furthermore, this study 
showed that CVME induces apoptosis as indicated by a significant increase of 
apoptotic cell percentage (p<0.05) when compared with untreated cells. CVME was 
also found to contain numbers of pharmacologically bioactive compounds that possess 
anticancer activities such as phytol and 10-undecenoic acid. Hazardous heavy metal 
analysis revealed that this plant contains a high concentration of chromium which may 
cause toxic side effects. Overall, this study demonstrates the potential applications of 
C. vespertilionis as an anticancer drug for breast cancer treatment.
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background of study 
Cancer is a condition of abnormal cell growth in the body that disobeys the normal 
rules of cell division and cell death. Cancer cells also have an abnormal structure and 
are unable to differentiate into functioning normal cells. This group of cancer cells will 
eventually form a tumor that has the potential to become malignant and metastasize to 
different parts of the body, thus jeopardize the normal physiologic body function 
(Umar et al., 2012). 
 
Cancer is a second leading cause of death worldwide, estimated to cause 9.6 million 
of death in 2018 (WHO, 2018). It is also predicted that the cases of cancer diagnosed 
will increase and reach 24 million by 2035 (GLOBOCAN, 2012). In Malaysia, 12% 
of mortality in the hospital were caused by cancer, making it as a major cause of death 
after cardiovascular and blood diseases. The most common type of cancer detected 
among Malaysians was breast cancer followed by colorectal and respiratory tract 
cancers (Azizah et al., 2016). Breast cancer was also a common malignancy among 
women in the United States, estimated to affect 268,670 individuals and cause more 
than 40,000 of death in 2018 (Siegel et al., 2018).  
 
The increment of breast cancer cases and the toxic side effects of current breast cancer 
treatments have created a demand for new therapeutic agents to treat the disease. In 
this regard, the medicinal plant have been identified as having the potential to be 
develop into staple drugs for cancer. The secondary metabolites produced by some 
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plants have been scientifically reported by researchers to be effective in treating a 
number of illnesses and diseases such as bacterial infection, diabetes and physical 
injuries (Raman et al., 2012; Reghu et al., 2017; Sharma et al., 2013). Moreover, the 
medicinal plant has been preferred as they have been successfully isolated, modified, 
synthesized and approved to be used as anticancer drugs for years (Demain and 
Vaishnav, 2011). To be specific, 108 medicinal plant‐based drugs were studied in 
various testing procedures such as in preclinical, clinical phases I to III, and 
preregistration in early 2008 (Harvey, 2008). 
 
The search for potential anticancer agents still continues until recent time and one of 
the plants screened to have anticancer properties is Christia vespertilionis (CV) or 
locally known as ‘daun rerama’ (Nguyen-Pouplin et al., 2007). This plant has 
‘butterfly’ shaped leaves, widespread in tropical Southeast Asia and native in Malaysia. 
Recently, this plant was promoted as a ‘cancer remedy’ among some herb’s 
practitioners in the local market and commercialized in the form of tea. Thus, raises 
an awareness regarding the safety and efficiency of C. vespertilionis in treating cancer. 
Therefore, the present study was designed to assess the cytotoxicity of C. vespertilionis 
towards breast cancer cell lines. Analysis of the mode of cell death was also conducted 
to confirm either the cell dead through apoptosis or necrosis mechanism. 
 
1.2 Rationale of study 
The risk and detrimental side effects of radiotherapy and chemotherapy for cancer 
treatment are acknowledged to fast compensating their benefits. Thus, increasing the 
urged for the development of a new therapeutic agent. Medicinal plants have gained 
an attention as a source of novel anticancer drugs by the scientific community. They 
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have been perceived as safe by the public because it is natural and have been 
traditionally used. Nevertheless, their natural origin is not a guarantee of safety as 
concerning many toxic cases due to the herbal product consumption had been noted. 
Recently, Christia vespertilionis-based products which have been claimed to have 
anticancer activity have been distributed and consumed in Malaysia, even though the 
scientific evidence of anticancer activities of C. vespertilionis is still not fully 
elucidated. Moreover, the toxic profile of C. vespertilionis also is not fully understood. 
Hence, through the cytotoxic and safety evaluation conducted in this study, it could 
provide knowledge and safeguard to the public regarding the efficacy and safety of C. 
vespertilionis.  
 
1.3 Objectives of the study 
1.3.1 General objective 
The general objective of this study was to evaluate the cytotoxic activity of C. 
vespertilionis aqueous extract (CVAE) and C. vespertilionis methanol extract (CVME) 
in MDA-MB-231 and MCF-7 breast cancer cell lines. 
 
1.3.2 Specific objectives 
1. To evaluate the IC50 of CVAE and CVME in MDA-MB-231 and MCF-7 cell 
lines. 
2. To determine the mode of cell death after treatment with CVME or CVAE. 
3. To identify the phytochemicals present in CVME or CVAE by using gas 
chromatography-mass spectrometry (GC-MS). 
4. To identify the heavy metals present in CV by using inductively coupled 
plasma-mass spectrometry (ICP-MS). 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Cancer 
Cancer is an abnormal cell which divides uncontrollably beyond their natural 
boundaries. Accumulating cancer cell can form a mass of tissue or tumor (Aktipis et 
al., 2015). The type of tumor can be divided into benign or malignant. If the tumor 
does not occupy the surrounding tissue, it is denoted as benign. In contrast, if the tumor 
successfully invades to distant part of the tissues through the local spread, blood, and 
lymphatic vessels, it is said to have metastasized and denoted as malignant (Vogelstein 
et al., 2013).  
 
Cancer cells act intelligently in many ways to maintain their survival. One important 
myriad of cancer cells is the capability to avoid apoptosis; a natural programmed cell 
death (PCD). Besides, cancer cells can sustain proliferative signalling, evading growth 
suppressors, activating metastasis, enabling replicative immortality and inducing 
angiogenesis during metastasis. Cancer cells also can avoid immune cell destruction, 
deregulating cellular energetics, contain mutated genome and capable of promoting 
inflammation (Hanahan and Weinberg, 2011). 
 
There are over 100 types of cancer recognized and they are classified in two ways; by 
the location in the body and by the type of cell or tissue that cancer arises (histological 
type). Based on the histological type, cancer can be classified into carcinoma, sarcoma, 
myeloma, lymphoma, and leukaemia. Carcinoma is an epithelial tissue malignancies 
account for 80-90% of cancer cases worldwide (Almeida and Barry, 2011). Breast, 
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lung, colorectal, skin and prostate cancer are the examples of cancer that can be 
classified under carcinoma (National Cancer Institute, 2015). The global incidence and 
death of top five cancers is shown in Table 2.1. 
 
2.1.1 Breast cancer 
Breast cancer is characterized by abnormal growth of cells in the mammary epithelial 
tissue (Hinck and Näthke, 2014). The type of breast cancer depends on the type of cells 
in the breast that turn into cancer. The most common type of breast cancer is ductal 
carcinoma; cancer cells that grow from the ducts of the breast, and lobular carcinoma; 
cancer cells that grow from the lobules of the breast. Both types of breast cancer cells 
can invade surrounding tissues and metastasize to distant parts of the body through 
blood and lymphatic vessel (Centre for Disease Control, 2018).  
 
2.1.2 Epidemiology of breast cancer 
Breast cancer is the most common cancer worldwide diagnosed with an estimated 2.4 
million incidence cases reported in 2015 (Fitzmaurice et al., 2017). In the United States, 
63,960 cases of carcinoma in situ and 87,290 cases of melanoma in situ of breast cancer 
were expected to be diagnosed in 2018 (Siegel et al., 2018). In Malaysia, breast cancer 
accounted for 32.1% of all cancers among women with estimated number of 18,206 
cases from 2007-2011. Based on ethnic group, the incidence of breast cancer was 
found to be the highest among Chinese women with the ratio of 1 in 22 people followed 
by Indian with the ratio of 1 in 24 people and the least is among Malay with the ratio 
of 1 in 35 people (Azizah et al., 2016).  
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Table 2.1 Global incidence and deaths for top five cancers in 2015. Adapted from 
Fitzmaurice et al. (2017) 
 
  
Ranking Cancer Incident Cases, 
Thousands 
Deaths, Thousands 
1 Breast  2422 534 
2 Tracheal, bronchus, and lung 2019 1722 
3 Colon and rectum cancer 1653 832 
4 Prostate 1618 366 
5 Stomach 1313 819 
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2.1.3 Breast cancer treatment 
According to Senkus et al. (2015), the treatment of breast cancer was given according 
to the cancer stage identified by node-tumor-metastasis staging. For stage I and II, 
mastectomy or breast-conserving surgery is the preferred treatment. For breast-
conserving surgery, radiation therapy is given after the surgery to reduce local 
recurrence and increase the survival rate (Clarke et al., 2005). Early stage breast cancer 
patients also receive adjuvant systematic therapies. The choice of adjuvant systematic 
therapies are endocrine therapy, tissue-targeted therapy, and chemotherapy. For stage 
III, the standard treatments are induction chemotherapy followed by surgery and 
radiation therapy. While, for stage IV, the treatments are endocrine therapy or 
chemotherapy. (Maughan and Lutterbie, 2010). The type of therapy and list of 
medication commonly used to treat breast cancer is shown in Table 2.2. 
 
2.1.3.1 Tamoxifen 
Tamoxifen is a drug that has been used for the treatment of estrogen receptor-positive 
breast cancer for more than 30 years. It has been used in both adjuvant and metastatic 
settings (Matteo et al., 2012). Tamoxifen can be used alone or in combination with 
chemotherapy to treat advanced breast cancer (Fisher et al., 1998). Despite its 
effectiveness in preventing recurrence and treat breast cancer, tamoxifen has been 
associated with several side effects such as increased the risk of developing uterine 
cancer, endometrial cancer, blood clots, stroke and cataracts (Sugerman, 2013). 
Therefore, the search for a new therapy that has less adverse side effects is in huge 
demand nowadays to treat breast cancer. 
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Table 2.2   Medication used in the treatment of breast cancer. Adapted from Maughan 
and Lutterbie (2010) 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Type of therapy Medication 
Chemotherapy Doxorubicin  
Epirubicin  
Docetaxel 
Paclitaxel 
Endocrine Anastrozole  
Exemestane  
Letrozole  
Goserelin  
Tamoxifen 
Tissue-targeted Trastuzumab  
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2.1.3.2 Side effects of cancer treatments 
Treatments for cancer such as surgery, radiation, hormonal therapy, and chemotherapy 
come with a burden of side effects to the cancer patients (Cleeland et al., 2012). The 
most often side effect experienced by cancer patients is fatigue, estimated to affect 
between 60% to 90% of patients during their treatment or survivorship (Bower et al., 
2000). This cancer-related fatigue is usually accompanied with other symptoms such 
as reduce cognitive function, insomnia, depression, and anxiety (Valentine and Meyers, 
2001). To be worsen, fatigue can effect patients’ compliance with medical treatment 
as reported by Berger et al. (2015). 
 
 Radiotherapy is a choice of treatment for cancer patient that has many deleterious side 
effects. Radiotherapy utilizes radiation that can damage the DNA of both cancerous 
and normal cells and inhibiting its ability to reproduce (Berkey, 2010). The most often 
side effects associated with radiotherapy are hair loss, weight changes and anemia. 
Radiotherapy also can cause radiation dermatitis such as itching, burning, scaling, 
pigmentation changes, and ulceration (Berger et al., 2011; Berkey, 2010). For breast 
cancer patients receiving radiotherapy, cardiovascular disease and radiation 
pneumonitis are well-recognize adverse effect. The risk of these side effects increases 
with longer follow-up of treatment and increases dose of radiation (Adams et al., 2003; 
Monsuez et al., 2010). Besides, cancer patients receiving chemotherapy were also 
reported to develop several side effects such as thrombosis, a condition of blood vessel 
blockage due to blood clot (Swystun et al., 2011) and early menopause among female 
young patients survivors (Partridge et al., 2008). 
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2.2  Mechanism of cell death in cancer  
2.2.1 Apoptosis 
Cell division is a normal physiologic process that needs to be counterbalanced by cell 
death. This crucial cell death process is known as apoptosis or PCD. The term 
“apoptosis” was introduced by Kerr to describe a form of hepatocellular cell death in 
ischemic liver disease (Kerr et al., 1972). The morphological features of apoptosis are 
membrane blebbing, cytoplasmic shrinkage, nuclear chromatin condensation, and loss 
of adhesion to neighbour cells and extracellular matrix followed by phagocytosis of 
the fragments by nearby cells (Hotchkiss et al., 2009) (Figure 2.1). Meanwhile, the 
biochemical changes of apoptosis are activation of proteases (caspases), chromosomal 
DNA cleavage into internucleosomal fragments, phosphatidylserine externalization 
and intracellular substrate cleavage by proteolysis (Ouyang et al., 2012).  
 
Apoptosis was reported to be dysregulated and lose its beneficial effect in numerous 
pathological conditions such as auto-immune disease, Alzheimer’s disease, 
Parkinson’s disease as well as cancer (Portt et al., 2011). According to Hanahan and 
Weinberg (2011), one of the cancer biology features is the imbalance between cell 
proliferation and apoptotic cell death as cancer cell was known to be able to avoid 
PCD. Thus, the search for a therapeutic agent that can induce apoptosis mode of cell 
death to treat cancer has been an indispensable approach by many studies as apoptosis 
is one of the important markers of potential anticancer drugs. In this regards, 
researchers have identified that some medicinal plants and their bioactive compounds 
capable of inducing apoptosis that is blocked in cancer cells (Safarzadeh et al., 2014) 
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Figure 2.1  Cytology and morphological hallmarks of apoptosis (Nunes et al., 2014) 
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2.2.2 Necrosis 
Necrosis is another form of cell death. Morphologically, necrotic cell death can be 
characterized by a gain in cell volume, swelling of organelles such as mitochondria 
and endoplasmic reticulum, plasma membrane rupture and loss of intracellular 
contents to extracellular matrix (Figure 2.2). The biochemical hallmarks of apoptosis 
such as activation of proteases (caspases) and fragmentation of oligonucleosomal 
DNA are usually absent in necrotic cells (Proskuryakov and Gabai, 2010).  
 
Necrosis occurs due to several factors such as physicochemical trauma, and also during 
viral and bacterial infection (Mohammad et al., 2015). Besides, necrosis is a common 
feature of human solid tumors in the core region due to oxygen and glucose depletion 
(Ouyang et al., 2012). Necrosis also associated with activated angiogenesis, reduced 
vascular maturation and presence of vascular invasion. Consequently, leads to the 
tumor vascular formation and metastatic spread (Stefansson et al., 2006). In breast 
cancer, necrosis has been related to high-grade disease, increased tumor size and high 
micro vessel density. While, in endometrial cancer, necrosis is associated with increase 
in tumor proliferation rate (Bredholt et al., 2015). 
 
According to Portt et al. (2011),  necrosis is an alternative cellular suicide pathway if 
the normal apoptosis is blocked or defected. However, the inflammatory reaction 
produced from the necrotic cell was reported to promote cancer cell growth because 
the immune cells which react to the inflammation produced essential cytokines to 
nurture the surviving cancer cells (Vakkila and Lotze, 2004). Briefly, these evidences 
bring into a suggestion that necrosis form of cell death is highly up regulated during 
cancer progression.          
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Figure 2.2  Cytology and morphological hallmarks of necrosis (Nunes et al., 2014) 
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2.3 Medicinal plants  
2.3.1 Medicinal plants as an anticancer agent 
For decades, secondary metabolites or phytochemical naturally produced by medicinal 
plants were utilized as a source of drug candidates for various ailments including 
cancer. In fact, 48 out of 65 new drugs registered from 1981-2002 for cancer treatment 
were derived from medicinal plants. For example are vincristine (Oncovin®) from 
Catharanthus roseus plant and paclitaxel (Taxol®) from Taxus brevifolia plant which 
have been used to treat several neoplasms including breast cancer (Nobili et al., 2009; 
Safarzadeh et al., 2014). Plants are also rich with other phytochemicals that are 
reported to have anticancer activities such as polyphenols, flavonoids and plant 
hormone; brassinosteroids (M.Greenwell, 2015).  
 
2.3.2 Medicinal plants induce apoptosis 
Apoptosis induction is one of the ideal characteristics of the anticancer agent as it does 
not elicit an inflammatory reaction. Recent findings suggested that natural compounds 
have the capability to stimulate apoptosis in cancer cells. A few examples of the 
phytochemicals that are capable of inducing apoptosis in cancer cells are 
epigallocatechin gallate (EGCG) from green tea, resveratrol from the skin of red 
grapes, and curcumin from the rhizome of Curcuma species (Mohammad et al., 2015). 
EGCG was reported to induce apoptosis by inhibiting proteasome activity thus led to 
the accumulation of IkB-ɑ and p27 protein that eventually cause growth arrest (Kazi 
et al., 2003). Meanwhile, resveratrol and curcumin induce apoptosis by increasing the 
sensitivity of resistant cancer cells and elevate pro-apoptotic factor Bax respectively 
(Hayun et al., 2009; Sprouse and Herbert, 2014). 
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2.3.3 Safety of medicinal plants 
Nowadays, the safety of food including medicinal plants is in increase concern. Many 
adverse side effects have been reported due to consumption of medicinal plants such 
as direct toxic effects, allergic reactions, effects from contaminants, and interactions 
with drugs and other herbs (Bent and Ko, 2004). Some medicinal plants and their 
constituents has been shown to cause liver injury or carcinogenicity as reported by 
Moreira et al. (2014). For example are Aristolochia sp. that can cause upper tract 
urothelial carcinoma (Chen et al., 2013) and Piper methysticum G. Forst. that can cause 
hepatocellular and cholestasis pattern of liver injury (Olsen et al., 2011). These reports 
suggest that even though the plant was perceived as ‘natural’ and had been used for a 
long time as a traditional medicine, it does not ensure the safety and effectiveness of 
the medicinal plants. In this regards, strict evaluation of plant safety is vital before 
being commercialized as a product. 
 
2.3.4 Christia vespertilionis (CV) 
2.3.4.1 Ethnobotanical view 
Christia vespertilionis (CV) is commonly known as a butterfly wing or ‘rerama’ 
(butterfly in Malay). This plant is a non-climbing perennial herb that comes from 
Fabaceae family and can be found widespread in tropical Southeast Asia. This plant is 
one of the popular ornamental plants because of its uniquely shaped trifoliate leaves. 
The juvenile leaves of CV usually have a purple tint and dark green along prominent 
veins and the plant can grow until 60-120 cm. The picture of CV plants is shown in 
Figure 2.2.  
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Figure 2.3   Christia vespertilionis plant. Retrieved from 
https://sv.m.wikipedia.org/wiki/Fil:Christia_vespertilionis_Blanco1.201.j
pg 
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2.3.4.2 Traditional uses 
Traditionally, the whole plant of CV has been reported to be used for the relief of 
tuberculosis, bronchitis, inflamed tonsils, muscle weakness, snake bites, bone fracture, 
cold and to increase blood circulation (Brach and Song, 2006; Bunawan et al., 2015). 
Besides, CV was also used for the treatment of scabies by applying the crushed fresh 
leaves topically (Upadhyay et al., 2013). 
 
2.3.4.3 Phytochemicals 
CV was reported to contain various phytochemicals including alkaloids, pheophorbid-
a (Chlorophyll derivative), isoquinoline alkaloids, triterpenes, fatty acids, phenols, 
alkanes, palmitine, corynoxidine, and long chained alcohols (Hofer et al., 2013). 
Besides, CV also contains other phytochemicals such as christine, christanoate, 
pentacyclic triterpenes, flavonoid, steroids, and monoterpene as reported by Upadhyay 
et al., (2013). 
 
2.3.4.4 Anticancer activity of CV 
A study conducted by Nguyen-Pouplin et al. (2007) is one of an early study that 
highlighted the anticancer potential of CV extract. The study reported that the 
cyclohexane extract of CV showed high cytotoxicity against human cervix carcinoma 
cells Hela. Furthermore, CV extracts also showed high cytotoxicity against 
neuroendocrine tumor as studied by Hofer et al. (2013). The study concluded that ethyl 
acetate fraction of CV yields highest cytotoxic activity against human medullary 
thyroid carcinoma and human small intestinal neuroendocrine tumor cell lines. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Materials 
3.1.1 General instruments and apparatus 
All general instruments and apparatus used in this study are listed in Table 3.1 
 
3.1.2 Consumable items 
All consumable items used in this study are listed in Table 3.2 
 
3.1.3 Chemicals and reagents 
All chemicals and reagents used in this study are listed in Table 3.3 
 
3.1.4 Plant materials 
The green butterfly wing of Christia vespertilionis plant was bought from Rural 
Transformation Centre Kelantan, Malaysia. The complete set of the plant was sent to 
Herbarium Kulliyah of Pharmacy, International Islamic University Malaysia and the 
taxonomic identity of the plant was authenticated by Dr Shamsul Khamis, a botanist. 
The voucher specimen is PPIUM 0273-1 and the scientific name of the plant was 
obtained. The scientific classification of CV was identified belongs to the genus of 
Christia and species of vespertilionis. 
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Table  3.1 General instruments and apparatus used in this study 
 
Instruments and apparatus Manufacturer 
Analytical balance Denver instrument, USA 
Biological safety cabinet Thermo Fisher Scientific, USA 
Centrifuge Hettich, Germany 
CO2 incubator Heraeus, Japan 
Deep freezer -80 ºC Sanyo, Japan 
Drying oven Binder GmBH, Germany 
Flow cytometer (FACS Calibur) Beckman-Coulter, USA 
Fridge (-4 ºC and -20 ºC) SHARP, Japan 
Fume hood ERLA, Malaysia 
GC-MS Conquer Scientific, USA 
Grinder Buffalo Machinery Co. Ltd., Taiwan 
Inverted microscope Olympus, Japan 
Microplate reader Biorad, USA 
MiniSpin Micro centrifuge Eppendorf, Germany 
Orbital shaker Heidolph, UK 
Rotary evaporator Heidolph, UK 
Spectrophotometer Shimadzu Corp., Japan 
Vortex mixer ERLA, Malaysia 
Water bath Memmert, Germany 
Hemacytometer set LO-laboroptik Ltd, UK 
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Table 3.2  Consumables used in this study 
 
Consumables Manufacturers 
96-wells plates Costar Cornin, USA 
6-wells plate SPL life science, Korea 
0.22 µm syringe filter membrane TPP, Switzerland 
Centrifuge tube (1.5 ml, 15 ml) Axygen Scientific, USA 
Cryogenic vials Invitrogen, USA 
Falcon tube (50 ml) Thermo Fisher Scientific, USA 
Filter paper Whatman, UK 
Flow cytometry tube BD, USA 
Plastic petri dish Thermo Fisher Scientific, USA 
Pipette tips (1-1000 µl) Axygen Scientific, USA 
Pipette tips (1-200 µl) Axygen Scientific, USA 
Pipette tips (0.2-10 µl) Thermo Fisher Scientific, USA 
Serological pipette TPP, Switzerland 
Syringe (10 ml) BD, USA 
T25 tissue culture flask TPP, Switzerland 
T75 tissue culture flask TPP, Switzerland 
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Table 3.3  Chemicals and reagents used in this study 
 
Chemical or reagents Manufacturer 
3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) powder 
Amresco, Inc. USA 
Absolute ethanol Merck, Germany 
Dimethyl sulfoxide (DMSO) VWR life science, USA 
Dulbecco’s Modified Eagle Medium (DMEM) ATCC, USA 
Ethyl acetate HmbG, Malaysia 
Fetal bovine serum Gibco Laboratories, USA 
Methanol Merck, Germany 
Penicillin streptomycin Gibco Laboratories, USA 
Petroleum ether HmbG, Malaysia 
Phosphate buffer saline (PBS) Invitrogen, USA 
Propidium iodide Merck, Germany 
Tamoxifen Sigma-Aldrich, USA 
Trypan blue Gibco Laboratories, USA 
Trypsin-EDTA 0.25% Gibco Laboratories, USA 
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3.2 Methods 
This study started with the collection and identification of the plant. Then, extraction 
was performed to obtain the extracts. The extracts obtained were used in MTT assay 
to evaluate the IC50 of the extracts against cancerous and non-cancerous cell lines. 
Then, the cytotoxicity of the extracts was further evaluated by Annexin V apoptosis 
assay to determine the mode of cell death. Concurrently, identification of bioactive 
compounds in the most potent CV extract and heavy metals in the leaves powder of 
CV were conducted by using GC-MS and ICP-MS, respectively. The flowchart of this 
study is shown in Figure  3.
 23 
 
 
Figure 3.1  Experimental flowchart 
Collection and identification of C. 
vespertilionis 
Successive extraction by 
maceration method 
MTT Assay 
Annexin V Apoptosis Assay  
Statistical analysis 
Heavy metal screening 
by ICP-MS 
Phytochemicals 
screening by GC-MS 
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3.2.1 Extraction of CV leaves 
3.2.1.1 Preparation of CV leave extracts 
The fresh leaves of CV were cleaned and rinsed with tap water and distilled water to 
remove surface pollutants. After that, the leaves were dried in an oven at 40ºC in a 
ventilated drying oven for four days or until constant weight was measured. Then, the 
leaves were ground into fine powder by using a grinding mill. Then. The ground 
sample was stored in the chiller at 4ºC until further use. 
 
The ground CV leaves were extracted successively by maceration method in petroleum 
ether, ethyl acetate, methanol and water (1:10 plant/solvent ratio) for 24 hours in each 
solvent as shown in Figure 3.2. In this study, 50 g of the ground CV leave were 
macerated in 500 ml of solvents. After 24 hours of extraction, the extract solutions 
were filtered by using Whatman filter paper to remove any left residues. Then, the 
extracts were concentrated under reduced pressure until complete elimination of 
organic solvents and subsequently freeze-dried for water solvent providing CV 
petroleum ether extract (CVPEE), CV ethyl acetate extract (CVEAE), CV methanol 
extract (CVME) and CV aqueous extract (CVAE). All extracts were stored in the 
chiller at 4ºC until further use. The yields of the extracts were weighed by electronic 
balance and calculated by using the following formula: 
 
Yield (%) =  
Weight of extract (g)
Weight of sample taken for extraction (g)
